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This dose-ranging study assessed the bronchodilator efﬁcacy and tolerability of
indacaterol, a novel once-daily inhaled b2-agonist, in subjects clinically diagnosed with
COPD. Comparative data with tiotropium were collected.
In the double-blind, core period of the study, 635 subjects with COPD (prebronchodilator
FEV1X40% of predicted and X1.0 L; FEV1/FVC o70%) were randomized to receive
indacaterol 50, 100, 200 or 400 mg or placebo via multi-dose dry powder inhaler, or
indacaterol 400 mg via single-dose dry powder inhaler, once daily for 7 days. After
completing double-blind treatment and washout, a subset of subjects from each treatment
group entered an open-label extension and received tiotropium 18 mg once daily for 8 days.
The primary efﬁcacy variable was the trough bronchodilator effect: standardized area
under the FEV1 curve between 22 and 24 h post-dose (FEV1 AUC22–24h) on Day 1.
Clinically relevant improvements versus placebo in FEV1 AUC22–24h were seen for 400 and
200mg doses on Day 1 and all doses on Day 7. All indacaterol doses signiﬁcantly (Po0.05)
increased FEV1 from 5min to 24h post-dose; the 400 and 200mg doses were most effective. All
doses were well tolerated. Indacaterol trough FEV1 levels compared favorably with the
improvement seen by Day 8 in subjects treated with tiotropium in the open-label extension.
The results conﬁrm that indacaterol has a 24-h duration of bronchodilator effect and a fast
onset of action in COPD and suggest that indacaterol could be an effective once-daily inhaledElsevier Ltd. All rights reserved.
559 7313; fax: +1 402 559 4878.
u (S. Rennard).
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S. Rennard et al.1034b2-agonist bronchodilator. Indacaterol demonstrated a good overall safety and tolerability
proﬁle.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by airﬂow limitation that is not fully reversible and is
generally progressive. Bronchodilators, which can improve
airﬂow, are central to symptom management of COPD. For
subjects who experience symptoms on a regular basis,
regular treatment with one or more long-acting bronchodi-
lators is recommended.1 For this purpose inhaled agents are
recommended because of their greater therapeutic ratio
and long-acting agents are preferred because of conveni-
ence and, more importantly, their ability to provide
sustained bronchodilation through the day and night.
Two long-acting b2-agonists are currently available,
formoterol and salmeterol, which provide bronchodilation
for approximately 12 h and are taken twice daily.2 Both have
been shown to be effective and well tolerated in the
treatment of subjects with COPD.3–5 Tiotropium, an anti-
cholinergic agent with a duration of action of more than 24 h
on once-daily dosing,6 has also been shown to be effective in
the management of subjects with COPD.7 Compared with
four-times-daily dosing with the anticholinergic ipratro-
pium, once-daily dosing with tiotropium has delivered
improvements in a range of outcomes, including dyspnea
and exacerbations.8 In chronic diseases like COPD, adher-
ence to treatment improves as treatment regimens are
simpliﬁed, for example by reduced dosing frequency.9 This is
an important consideration, since improved adherence to
therapy has been demonstrated to be associated with
improved outcomes in a range of chronic disease states,
including asthma,10 diabetes and hypertension.11,12
Indacaterol is a selective long-acting b2-agonist in
development for the treatment of COPD and in combination
with an inhaled corticosteroid, asthma. Indacaterol has
demonstrated 24-h bronchodilation on repetitive once-daily
dosing in subjects with COPD and in asthma, together with a
good overall safety proﬁle.13,14
The primary objective of the current study was to ﬁnd an
indacaterol dose that is effective over 24 h and well
tolerated in subjects with COPD. The study was extended
to include a period of open-label treatment with tiotropium,
to generate data for a within-subject comparison with the
double-blind period of indacaterol treatment.iThe Certihaler was jointly developed by Novartis and SkyePharma
AG and utilizes SkyePharma’s proprietary formulation and device
technologies, SkyeProtectTM and SkyeHalerTM, respectively.Methods
Design
The study consisted of two treatment periods. The core
period was a 7-day, randomized, double-blind, placebo-
controlled dose-ranging trial of indacaterol. This was
followed by an 8-day tiotropium open-label extension
period. The two periods were separated by a minimum of
7 days’ washout.In the core period, subjects were randomized using a
validated automated system to receive indacaterol 50, 100,
200 or 400 mg once daily via multi-dose dry powder inhaler
(MDDPI; CertihalerTM),i indacaterol 400 mg once daily via a
single-dose dry powder inhaler (SDDPI) or placebo via an
SDDPI. The 400 mg SDDPI dose was included to allow
reference to previous indacaterol studies where administra-
tion was via SDDPI. To maintain blinding, subjects inhaled
treatment as two puffs from the MDDPIs (50, 100 or 200 mg of
active drug or placebo) and one puff from the SDDPI (400 mg
or placebo). In the extension (open-label) period, subjects
received tiotropium bromide 18 mg once daily via the
manufacturer’s proprietary inhalation device. All daily doses
were inhaled between 08:00 and 10:00 h.
The research protocol was approved by the relevant
institutional review boards or ethics committees, and all
subjects gave written informed consent.Inclusion and exclusion criteria
The study included males and females aged 40–75 years,
with a clinical diagnosis of COPD, a smoking history of at
least 20 pack-years (current or past smokers); (pre-
bronchodilator) FEV1 at both the screening visit and the
ﬁrst study treatment visit X40% of the predicted normal
value and X1.0 L (after a washout period, during which
salbutamol had not been inhaled for at least 6 h, any other
short-acting b2-agonist had not been inhaled for at least 12 h
and any long-acting b2-agonist had not been inhaled for at
least 24 h); and a pre-bronchodilator FEV1/forced vital
capacity (FVC) o70%.
Subjects were permitted to continue into the open-label
period provided they had completed the core period, had at
least one FEV1 measurement in the period 22–24 h post-dose
on Day 7 of the double-blind period, consented to continuing
in the second period, and met the same spirometric
inclusion criteria at the ﬁrst visit of the open-label period.
Among those excluded from the study were: subjects
who had been hospitalized for an exacerbation of their
airways disease in the 6 months prior to the screening
visit or between the screening and baseline visits; subjects
with a history of asthma (e.g. blood eosinophil count4400/
mm3; onset of symptoms prior to age 40 years); those
with seasonal or perennial allergic rhinitis; or subjects
with a signiﬁcant unstable cardiovascular or metabolic co-
morbidity.
At the screening visit, subjects were trained to use the
inhaler devices and given written instructions on how to use
the SDDPI and MDDPI.
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Inhaled salbutamol was permitted as rescue medication but
was not to be taken within 6 h of the start of a study visit,
unless necessary.
Subjects were not permitted to use the following
medications prior to the screening visit (or start of the
extension period) for at least the minimum washout period
speciﬁed, or at any time during the study: tiotropium (7-day
washout; other than as supplied in the extension period);
short-acting anticholinergics (8 h); ﬁxed combinations of
b2-agonists and inhaled corticosteroids (24 h); long-acting
b2-agonists (24 h); short-acting b2-agonists, other than
permitted (salbutamol) rescue medication (12 h); non-
slow-release theophylline (72 h). Subjects were permitted
to take oral modiﬁed-release theophylline, providing they
had been stabilized for at least 1 month prior to screening.
Assessments and variables
Spirometry was performed pre-dose and at intervals post-
dose on Days 1 and 7 (5, 10, 15, 30min, 2, 3, 4, 22, 23 and
24 h on both days, and at 8 and 12 h post-dose on Day 7) of
the core period, and pre-dose and at intervals post-dose on
Days 1 and 8 (5, 10, 15, 30min, 1, 2, 3 and 4 h on both days
and at 22, 23 and 24 h on Day 8) of the open-label period.
The primary efﬁcacy variable was the difference in
standardized FEV1 area under the curve (AUC) at 22–24 h
post-dose (FEV1 AUC22–24 h) on Day 1 (core period) between
indacaterol (50, 100, 200 and 400 mg once daily delivered by
MDDPI) and placebo.
Secondary efﬁcacy variables in the core period were
standardized FEV1 AUC22–24 h on Days 1 and 7 for comparisons
other than the primary efﬁcacy variable, peak FEV1, and
FEV1, FVC, and forced expiratory ﬂow between 25% and 75%
of FVC (FEF2575%) at each individual time point post-dosing.
Secondary efﬁcacy variables in the open-label extension
period were standardized FEV1 AUC22–24 h on Day 8, and
standardized FEV1 AUC0–4 h on Days 1 and 8.
Safety assessments during the core period consisted of
monitoring and recording all adverse events and the regular
monitoring of hematology, blood chemistry and urine, and
the regular assessments of vital signs, electrocardiogram
(ECG), spirometry and physical condition. During the open-
label extension period, all adverse events were monitored
and recorded, but no other safety assessments were
performed.
Statistical analyses
All efﬁcacy analyses were performed on the intention-to-
treat (ITT) population, which included all subjects who were
randomized to receive treatment. All safety analyses were
performed on the safety population, which included all
subjects who received at least one dose of trial medication.
The primary variables were analyzed using an analysis of
covariance (ANCOVA) model, with treatment and center
(nested within country) as ﬁxed effects and baseline
measurement as a covariate, where the baseline measure-
ment was deﬁned as the value measured before the ﬁrst
study drug administration on Day 1. The secondary efﬁcacyvariables and key laboratory variables (serum potassium and
blood glucose) were analyzed using the same ANCOVA model
applied to the primary variables.
The extension-period analysis included a series of within-
subject pairwise comparisons, using data from the ITT
population who entered the extension period. Thus, for the
subset of subjects who continued in the extension period,
their (indacaterol) data from the core period were com-
pared with their (tiotropium) data from the extension
period. An ANCOVA was performed with a model including
treatment, subject and baseline FEV1. For the indacaterol
and placebo data, the baseline FEV1 was deﬁned as the
value measured pre-dose on Day 1 of the core period. For
the tiotropium data, the baseline FEV1 was deﬁned as the
value measured pre-dose on Day 1 of the extension period.
No testing for carry-over was performed because the
washout period was deemed to be sufﬁcient. For subjects
who continued into the extension, data from Days 1 and 8 of
the extension period were compared with data from Days 1
and 7 of the core period, to accommodate differences in
half life of indacaterol and tiotropium.
The data were analyzed by statisticians at Novartis
Pharma AG and Pharmaceutical Product Development, Inc.Sample size
The sample size calculation was based on the primary
efﬁcacy assessment, FEV1 AUC22–24 h on Day 1 of treatment.
A standard deviation of 350mL was chosen for the sample
size calculation, based on the assumption that the standard
deviation would be greater than that observed at 12 h post-
dose in previous studies in COPD owing to the longer
exposure in the present study (22–24 h).3,4 Taking into
account previous data, the study was powered for a
treatment difference of 150mL between the indacaterol
doses and placebo. Allowing for a 10% dropout rate, 110
subjects (with at least 99 evaluable subjects) per treatment
arm were needed to achieve sufﬁcient power to detect the
deﬁned treatment difference at a signiﬁcance level of 0.05,
based on a two-sample t-test. Therefore, 660 subjects
(including the SDDPI reference group) were to be rando-
mized to the study.
The estimated number of subjects needed to enter the
extension period was based on the expected FEV1 AUC22–24 h
on Day 8 of tiotropium treatment. A standard deviation of
250mL was chosen for the sample size estimation, based on
the results of previous studies. To detect a treatment
difference of 150mL in a within-subject comparison
between individual treatment groups and tiotropium bro-
mide with sufﬁcient power, 32 subjects following each
treatment sequence were needed. Assuming that subjects
entering the extension period would be randomly selected,
260 subjects entering the open-label study would provide a
high chance (40.99) of having at least 32 subjects in any
sequence.Pharmacokinetic assessments
For pharmacokinetic assessments, venous blood samples
were taken pre-dose, 15min, 1 and 4 h post-dose; urine was
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and seventh day of treatment.
Serum was prepared from blood and stored at 20 1C until
analysis. A 30mL aliquot of the urine collection was stored
at 20 1C until analysis. Indacaterol was determined by
means of a validated LC\MS\MS method, with a lower limit of
quantiﬁcation of 0.05 ng/mL in serum and 0.1 ng/mL in
urine. The area under the serum concentration–time curve
of indacaterol between 0 and 4 h after inhalation (AUC0–4 h)
was determined by the linear trapezoidal method.
Subjects were excluded from the pharmacokinetic ana-
lyses of serum data if samples were mislabelled, if the pre-
dose serum concentration was greater than any post-dose
concentrations, or if the concentration or sampling time
information was missing. If the urine collection interval was
shorter than 3.2 h or longer than 4.8 h on any given visit day,
or if the post-dose urine data (volume or concentration)
were missing, the subject’s urinary excretion data (Ae04 h)
were excluded from the urine pharmacokinetic analysis.
A linear model was used for analysis of logarithmically
transformed AUC0–4 h with treatment a ﬁxed effect. The
geometric mean and 90% conﬁdence interval (CI) for
AUC0–4 h were determined for each dose. The AUC-to-dose
relationship was investigated with a linear regression
analysis of the logarithmic data set. Given the dose range
tested in this study (i.e. an 8-fold increase), and assuming a
90% CI of 0.8–1.25 for the ratio of dose-normalized AUCs,
dose proportionality would be concluded if the 90% CI of the
slope of the regression line was completely within the range
of 0.89–1.11.15 For Ae0–4 h, the arithmetic mean and 90% CI
were determined for each dose.
Results
In total, 1,170 subjects were screened; 635 subjects were
randomized and treated between July and December 2004
at 102 centers in Belgium, Canada, Denmark, France,
Germany, Italy, Netherlands, Norway, Peru, Russia, Sweden,
Switzerland and USA. Most randomized subjects (98.1%)
completed the core period of the study. Similarly, 97.8% of
the 269 subjects in the extension period completed this
period. Demographics and baseline characteristics of the
subjects were broadly similar between treatment groups
(Table 1). Most subjects (95%) were Caucasian. The most
common COPD medications prior to the start of the study
were inhaled b2-agonist (31% of subjects) and inhaled
b2-agonist plus steroid (22%). Inhaled corticosteroids (with-
out concomitant b2-agonist) were taken byo2% of subjects.
Ten patients continued use of theophylline during the study
period.
Efﬁcacy
Core study
All doses of indacaterol were superior to placebo (Pp0.01)
for the primary efﬁcacy variable, FEV1 standardized
AUC22–24 h on Day 1, and on Day 7 (Figure 1). Improvements
of X120mL relative to placebo were observed with
indacaterol 200 and 400 mg (MDDPI and SDDPI) on Day 1,
and with all doses on Day 7.Serial FEV1 measurements on Day 1 (Figure 2A) showed
that all doses of indacaterol had a signiﬁcantly greater
effect than placebo (Po0.05) from 5min to 24 h post-dose.
The 24-h efﬁcacy was maintained on Day 7, with all doses
having a greater effect than placebo (Po0.001) at all time
points. Indacaterol 400 mg (MDDPI or SDDPI) was superior
(Po0.05) to 50 mg at all time points except 23 h post-dose.
Values for FEV1 measured pre-dose on Day 7 showed a
statistically signiﬁcant increase with all doses of indacaterol
relative to placebo (Po0.001), with mean (95% CI) increases
over placebo of 160 (100, 210), 160 (110, 220), 200 (150,
260), 230 (180, 290) and 220 (170, 280) mL for indacaterol
50, 100, 200 and 400 mg MDDPI and 400 mg SDDPI, respec-
tively.
For FVC, all doses of indacaterol were statistically
superior (Po0.01) to placebo at all time points up to 24 h
post-dose on Days 1 and 7 (Figure 2B). Signiﬁcant improve-
ments in FEF2575% (results not shown) were achieved with
indacaterol relative to placebo at several post-dose time
points. The 400 mg SDDPI dose signiﬁcantly increased
FEF2575% at all time points on Days 1 and 7 apart from the
24-h measurement on Day 7.
The use of rescue medication during the core period was
higher in the placebo group than in any of the active groups
on both Day 1 (25% versus 11–23%) and Day 7 (24% versus
12–17%).Indacaterol pharmacokinetics
In general, Cmax was observed between 15min and 1 h post-
dose. There was high inter-subject variability with respect
to serum and urine pharmacokinetic variables (AUC0–4 h,
Ae0–4 h) (Table 2). This was most pronounced with the 50 mg
dose on Day 1, where many serum and urine concentrations
were below the limit of quantiﬁcation.
The AUC0–4 h of indacaterol increased with dose on Days 1
and 7. Over the eight-fold increase in dose, the model
predicted an increase of AUC0–4 h by a factor of 7.72 (90% CI:
4.88, 12.25) on Day 1 and 9.71 (90% CI: 6.40, 14.71) on Day
7, but formal dose-proportionality could not be concluded
because the 90% CIs of the slope of the linear regressions
were not included in the interval of 0.89–1.11. Geometric
mean serum AUCs on Day 7 were 1.3–2.2-fold higher than
those on Day 1 (Table 2). The AUC0–4 h values were similar at
the 400 mg dose level for indacaterol administered via the
MDDPI and SDDPI devices.
Urinary elimination (Ae04 h) represented less than 1% of
the dose regardless of the dose level and study day (Table 2).Open-label crossover extension period
For FEV1 AUC, all indacaterol doses (assessed during the core
period but including only the subset of subjects in each
dose group who continued in the extension) provided
comparable or superior efﬁcacy to tiotropium 18 mg (as-
sessed during the open-label extension period) from 0–4 h on
Day 1, and 0–4 h and 22–24 h on Day 7/8 (Figure 3). A similar
ranking was seen for FEV1 at individual post-dose time points
(Figure 4A).
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Table 1 Subject demographics and baseline characteristics.
Indacaterol Placebo n ¼ 107 Open-label
extension n ¼ 269
400 mg MDDPI
n ¼ 110
200 mg MDDPI
n ¼ 105
100 mg MDDPI
n ¼ 105
50 mg MDDPI
n ¼ 103
400 mg SDDPI
n ¼ 105
Age (years), mean (SD) 61.6 (8.18) 60.8 (7.97) 61.5 (8.50) 60.9 (8.08) 62.1 (7.90) 60.6 (8.32) 60.0 (7.69)
Female sex, n (%) 29 (26.4) 37 (35.2) 33 (31.4) 38 (36.9) 37 (35.2) 37 (34.6) 95 (35.3)
Duration of COPD
(years), mean (range)
6.7 (0.0–26.2) 7.3 (0.0–30.6) 7.6 (0.1–40.2) 7.1 (0.0–35.3) 7.0 (0.2–32.3) 6.9 (0.1–42.6) 6.7 (0.0–39.1)
Smoking history, n (%)
Ex-smoker 46 (41.8) 47 (44.8) 48 (45.7) 43 (41.7) 51 (48.6) 40 (37.4) 96 (35.7)
Current smoker 64 (58.2) 58 (55.2) 57 (54.3) 60 (58.3) 54 (51.4) 67 (62.6) 173 (64.3)
Estimated pack years,
mean (range)
47.2 (20–133) 46.0 (20–180) 47.7 (20–225) 47.0 (20–135) 47.7 (20–144) 43.6 (10–160) 48.3 (20–225)
Baseline spirometry
Prebronchodilator
FEV1 (L), mean (range)
1.69 (0.90–3.57) 1.76 (0.89–3.81) 1.69 (1.05–3.06) 1.68 (1.00–3.57) 1.69 (0.76–3.18) 1.68 (1.00–2.91) 1.71 (0.98–3.81)
Prebronchodilator
FEV1 (% predicted),
mean (range)
56.16
(40.49–95.01)
59.31
(37.54–101.03)
57.19
(31.34–96.39)
56.78
(39.81–99.44)
57.20
(39.58–92.38)
56.01
(31.79–97.65)
56.34
(37.54–96.39)
Post-bronchodilator
FEV1 (L), mean (range)
1.87 (0.80–3.54) 1.93 (1.04–4.00) 1.87 (1.00–3.50) 1.83 (1.06–3.78) 1.87 (0.84–3.70) 1.87 (1.05–3.37) 1.90 (0.96–4.00)
FEV1 reversibility (%),
mean (range)
11.40
(11.11–49.56)
11.26
(18.26–4.16)
10.84
(21.61–3.93)
10.09
(9.63–39.37)
10.88
(12.78–6.01)
11.71
(8.15–47.93)
11.44
(38.85–49.56)
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Figure 1 FEV1 time-standardized AUC between 22 and 24 h post-dose on Days 1 and 7. *Po0.01, **Po0.0001 versus placebo;
yPo0.05 versus 50 mg; zPo0.05 versus 100 mg; and zPo0.05 versus 200 mg.
S. Rennard et al.1038Post hoc efﬁcacy analysis
To verify that the results were not inﬂuenced by data from
subjects whose post-bronchodilator FEV1 was normal (en-
rollment criteria for FEV1 and FEV1/FVC were based on pre-
bronchodilator measurements), a post hoc analysis was
carried out including only data from subjects with post-
bronchodilator FEV1p80% predicted. This analysis included
559 subjects (88% of all subjects), with 89, 93, 88, 97, 95
and 97 receiving indacaterol 50, 100, 200 and 400 mg MDDPI,
and 400 mg SDDPI, and placebo, respectively. Of these
subjects, 248 entered the extension phase.
In subjects with post-bronchodilator FEV1p80%, for
indacaterol 50, 100, 200 and 400 mg MDDPI and 400 mg SDDPI,
respectively, the adjusted mean (95% CI) standardized FEV1
AUC22–24 h values were increased relative to placebo by 110
(54, 160), 100 (46, 150), 160 (100, 210), 190 (140, 240) and
240 (170, 290)mL on Day 1 (the primary endpoint in the ITT
analysis) and 150 (100, 210), 160 (110, 220), 170 (110, 230),
220 (160, 270) and 220 (160, 270)mL on Day 7 (all po0.001
versus placebo). Figure 4 compares the 24-h FEV1 proﬁles on
Days 7/8 for the ITT population (subset of subjects in core
and extension periods; Figure 4A) and for the subjects
within this population with post-bronchodilator FEV1p80%
(Figure 4B).Safety
The overall rate of adverse events in the core period was
similar across treatment groups (including placebo), with
the exception of the indacaterol 50 mg group, where the rate
was lower (Table 3). The most frequent adverse events were
headache and cough. The incidence of headache was
comparable across treatment groups (3.6–6.7%) apart from
a higher incidence (11.4%) in the 200 mg group. Cough (mild
and short-lived) occurred at a higher frequency in the
indacaterol groups compared with placebo (2.9–12.4%
versus 0.9%) with evidence that this was a dose-related
response. However, the incidence of cough decreased over
the course of the study such that, by Day 7, the incidence
with indacaterol was similar to that with placebo. The rateof other adverse events was low and there were no
meaningful differences between treatment groups.
Two adverse events were classed as serious; both were
considered unrelated to study drug. One subject receiving
indacaterol 200 mg was hospitalized for investigation follow-
ing the reporting of a pre-dose ECG suggestive of coronary
artery disease. This was a pre-existing condition. The second
serious adverse event was in a subject who suffered a pelvis
fracture in the follow-up period after taking indacaterol
50 mg. Three subjects discontinued the study because of
adverse events: one subject in the 400 mg MDDPI group had a
COPD exacerbation; one in the 200 mg group with coronary
artery disease as described above; and one subject in the
200 mg group had an episode of throat irritation.
There was no evidence of drug- or dose-related changes in
hematology and no clinically relevant differences between
groups in any of the biochemical variables measured. Mean
post-dose serum potassium values did not differ signiﬁcantly
between treatment groups, apart from a difference in mean
values for the 400 mg MDDPI dose versus placebo at a single
time point (Day 1, 1 h). Post-dose values below normal were
recorded for four, three, zero, six and seven subjects
receiving indacaterol 50, 100, 200, 400 mg via MDDPI and
400 mg via SDDPI, respectively, and for one placebo subject.
For blood glucose, the only statistically signiﬁcant
differences between indacaterol and placebo were observed
with the 400 mg SDDPI group, 1 h post-dose on Day 1
(adjusted mean [SE] 5.86 [0.111] and 5.34 [0.107]mmol/L
for indacaterol and placebo, respectively), and 1 h post-dose
on Day 7 (5.73 [0.129] and 5.24 [0.125]mmol/L). The only
statistically signiﬁcant differences between indacaterol
groups were between 400 mg SDDPI and 50 mg MDDPI on Day
1 at 15min (5.53 [0.078] and 5.23 [0.079]mmol/L, respec-
tively) and on Day 1 at 1 h post-dose (5.86 [0.111] and 5.38
[0.110]mmol/L). Maximum post-dose values higher than
normal were recorded for 22, 29, 17, 31 and 29 subjects on
indacaterol 50, 100, 200, 400 mg MDDPI and 400 mg SDDPI,
respectively, and for 23 placebo subjects.
There were no clinically signiﬁcant differences in mean
pulse rate or QTc interval between treatment groups, and no
drug-related trends in systolic or diastolic blood pressure.
There were no statistically signiﬁcant differences in mean
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Figure 2 (A) Adjusted mean FEV1 over 24 h on Day 1 (ITT population). All doses superior to placebo (Po0.05); 400 mg MDDPI and
SDDPI superior to 100 mg and 50mg at all timepoints (Po0.05); 400 mg MDDPI and 400 mg SDDPI superior to 200 mg (Po0.05) from 5min
to 12 h except 15min and 1 h; zPo0.05 versus 100 mg; and zPo0.05 versus 50 mg. (B) Adjusted mean FVC over 24 h on Day 1 (ITT
population). All doses superior to placebo (Pp0.005); 400 mg MDDPI superior to 200, 100 and 50mg at all timepoints (Pp0.05) apart
from one comparison (versus 200 mg at 22 h; P ¼ 0.0567); 400 mg SDDPI superior to 50 mg (Po0.05) at 5 and 30min and 12 and 22 h;
400 mg SDDPI superior to 100 mg (Po0.05) at 30min and 1, 8–24 h; and 400 mg SDDPI superior to 200 mg (Po0.05) at 8, 12, 22 and 24 h.
Indacaterol and tiotropium in obstructive airways disease 1039QTc interval between treatment groups, and no obvious
differences in the number of subjects with notable QTc
interval values or notable QTc interval increases. Fewer than
5% of subjects in any group had notably high values of QTc
interval by Fridericia’s formula. Two subjects, both in the
50 mg group, had increases 460ms.Discussion
The current study evaluated the bronchodilator effect of the
novel selective b2-adrenergic agonist indacaterol in subjects
clinically diagnosed with COPD. Indacaterol resulted in
signiﬁcant bronchodilation with an onset within 5min that
peaked after 2–3 h and was maintained for 24 h after dosingwith all doses evaluated. The magnitude of response
compared favorably with that observed in subjects who,
following washout, were subsequently treated with tiotro-
pium. Indacaterol was well tolerated. These results suggest
that indacaterol may be an effective once-daily b2-agonist
bronchodilator for use in the treatment of subjects with
COPD.
There was a clear dose-response over the range tested. In
the primary analysis, all indacaterol doses had a signiﬁcantly
greater effect than placebo on trough FEV1 on Day 1, with
the 200 and 400 mg doses exceeding the 120mL suggested as
the minimum clinically important difference for a bronch-
odilator in subjects with COPD.16,17 Turning to the secondary
comparisons of trough FEV1, the 400 mg doses (via MDDPI or
SDDPI), but not the 200 mg dose, were signiﬁcantly more
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Table 2 Geometric mean estimates and 90% CI for serum AUC0–4 h and arithmetic means7SD of urine elimination variable
Ae0–4 h per day, dose and device.
Day Dose (mg) Device AUC0–4 h (ng h/mL) Ae0–4 h (ng)
Geometric mean estimates Lower 90% CI Upper 90% CI Arithmetic mean 7SD
1 50 MDDPI 0.110 (n ¼ 12) 0.078 0.155 47 (n ¼ 13) 118
100 MDDPI 0.226 (n ¼ 13) 0.162 0.315 125 (n ¼ 13) 310
200 MDDPI 0.310 (n ¼ 22) 0.241 0.400 146 (n ¼ 19) 243
400 MDDPI 0.920 (n ¼ 21) 0.709 1.194 142 (n ¼ 15) 80
400 SDDPI 0.956 (n ¼ 23) 0.745 1.226 188 (n ¼ 17) 220
7 50 MDDPI 0.144 (n ¼ 19) 0.108 0.192 110 (n ¼ 15) 189
100 MDDPI 0.407 (n ¼ 14) 0.291 0.568 562 (n ¼ 13) 1692
200 MDDPI 0.687 (n ¼ 20) 0.520 0.909 334 (n ¼ 20) 451
400 MDDPI 1.490 (n ¼ 20) 1.127 1.970 589 (n ¼ 15) 416
400 SDDPI 1.532 (n ¼ 22) 1.174 2.000 715 (n ¼ 15) 638
Obtained by anti-log of the least-square means and the 90% CI thereof from an ANOVA model of log AUC0–4 h with treatment as ﬁxed
effect.
Figure 3 Adjusted mean time-standardized FEV1 AUC obtained on Days 1 and 8 of treatment with tiotropium (open-label evaluation
period) compared with data for the same subjects from Days 1 and 7 of double-blind treatment (core period; ITT population).
Po0.0001 tiotropium versus placebo at all timepoints; yPp0.001 versus tiotropium; zP ¼ 0.001 versus tiotropium; and zPo0.05
versus tiotropium.
S. Rennard et al.1040effective than lower doses. A similar pattern was seen for
trough FEV1 on Day 7, with a generally greater magnitude of
effect and a less clear-cut dose response. Both 400 mg doses
exceeded the threshold for clinical relevance (210mL
difference versus placebo) and were signiﬁcantly more
effective than the lowest dose. It is suggested that the
400 mg dose was, overall, the most effective in this study.
The magnitude of the bronchodilator effect achieved with
indacaterol compares favorably with that reported in other
studies for salmeterol, formoterol and tiotropium.3,5,18
While comparison between studies is problematic as
different groups of subjects may respond differently, the
current study also included a tiotropium treatment period.
As expected, tiotropium was an effective bronchodilator.
The comparisons between indacaterol and tiotropium should
be interpreted carefully, since tiotropium was administered
in an open-label fashion, and tiotropium was always
administered in the second treatment period. Bearing these
caveats in mind, among those who participated in thetiotropium treatment period, the bronchodilator response
to indacaterol compared favorably with that observed with
tiotropium in both the ﬁrst 4 h and at 24 h after dosing.
This is the ﬁrst study to compare once-daily inhaled
b2-agonist and anticholinergic bronchodilators. Although the
study design results in an indirect comparison, our results
suggest greater efﬁcacy of the b2-agonist. It will be
interesting to see if this is conﬁrmed in a study speciﬁcally
designed to address this question, and in a larger group of
patients with more severe disease. Previous studies are of
limited help in understanding if one class of bronchodilator
is superior to the other or if reported differences are due to
differing durations of action, e.g. once-daily tiotropium was
superior to four-times-daily ipratropium19 or twice-daily
salmeterol,7,20 and twice-daily formoterol was superior to
four-times-daily ipratropium.3 Comparisons of the short-
acting salbutamol and ipratropium showed little difference
between the two bronchodilator classes, both inhaled four
times daily21 or via nebulizer three times daily.22 In addition,
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Figure 4 Adjusted mean FEV1 on Day 7 of core period (indacaterol) and on Day 8 of the extension period (tiotropium) for: (A) the ITT
population subset completing the extension period. 400 mg SDDPI superior (Po0.001) to tiotropium at all timepoints; 400 mg MDDPI
superior (Po0.01) to tiotropium from 0–3 h and 22–24 h; 200 mg superior (Po0.05) to tiotropium from 0–30min and 22–23 h post-
dose; 100 mg superior (Po0.05) to tiotropium from 0–30min and 22–24 h post-dose; 50mg superior (Po0.05) to tiotropium at 5min;
and tiotropium superior to placebo (Po0.001) at all timepoints; and (B) for those in the same population with post-bronchodilator
FEV1p80% predicted. 400 mg SDDPI superior (Po0.001) to tiotropium at all timepoints; 400 mg MDDPI superior (Po0.01) to tiotropium
from 0–3 h and 22–24 h; 200 mg superior (Po0.05) to tiotropium at pre-dose, and 15–30min and 22–23 h post-dose; 100 mg superior
(Po0.05) to tiotropium from 5–30min and 22–24 h post-dose; and tiotropium superior to placebo (Po0.001) at all timepoints.
Indacaterol and tiotropium in obstructive airways disease 1041these studies generally compared the results in a single
population. It is possible that some subjects may respond
better to one class than another. Finally, these comparisons
are all confounded by the variable response of subjects to a
bronchodilator.23,24 The apparent superiority of indacaterol
over tiotropium in the present study may reﬂect a true
pharmacological effect.
While the present study was primarily aimed towards
studying subjects with moderate-to-severe COPD, we did
not take speciﬁc steps to exclude subjects with mild COPD.
Measures were taken to limit the inclusion of subjects with
asthma, including asthma history, onset of symptoms prior
to age 40 years and blood eosinophil count4400/mm3, anda history of seasonal or perennial allergic rhinitis. As this was
a dose-ranging study, we also set pre-bronchodilator lung
function inclusion criteria at screening in order to provide
sufﬁcient potential to demonstrate a sizeable bronchodila-
tor effect in order to help discriminate between indacaterol
doses. It is noteworthy, therefore, that subjects with post-
bronchodilator FEV1p80% responded at least as well to
indacaterol as did the overall population. While the overall
bronchodilator effect was slightly blunted, the differences
between indacaterol and placebo were maintained or even
increased. Indeed, all differences for indacaterol relative to
placebo for FEV1 standardized AUC22–24 h were higher for this
sub-group than those observed in the ITT population. The
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Table 3 Incidence of most frequent AEs (in 43% of patients in any group).
Primary system organ class Indacaterol
400 mg MDDPI
n ¼ 110
200 mg MDDPI
n ¼ 105
100 mg MDDPI
n ¼ 105
50mg MDDPI
n ¼ 103
400 mg SDDPI
n ¼ 105
Placebo
n ¼ 107
At least one adverse event 32 (29.1) 30 (28.6) 26 (24.8) 16 (15.5) 30 (28.6) 25 (23.4)
Respiratory, thoracic and
mediastinal disorders
16 (14.5) 10 (9.5) 7 (6.7) 3 (2.9) 15 (14.3) 2 (1.9)
Nervous system disorders 8 (7.3) 13 (12.4) 10 (9.5) 7 (6.8) 10 (9.5) 10 (9.3)
Infections and infestations 4 (3.6) 1 (1.0) 7 (6.7) 1 (1.0) 1 (1.0) 4 (3.7)
Gastrointestinal disorders 3 (2.7) 1 (1.0) 4 (3.8) 1 (1.0) 2 (1.9) 3 (2.8)
General disorders and
administration site conditions
2 (1.8) 2 (1.9) 2 (1.9) 2 (1.9) 1 (1.0) 4 (3.7)
Number (%) of subjects with AEs overall and by primary system organ class in the core period (safety population).
S. Rennard et al.1042favorable comparison of indacaterol relative to tiotropium
also held true for this subgroup, suggesting that the broader
inclusion criteria applied to the overall population did not
bias the results in favor of indacaterol.
Inhaled b2-agonist bronchodilators have several class-
related side effects due to systemic absorption. For
b2-selective agents, such as indacaterol, systemic side
effects are likely due to activation of b2-adrenoceptors,
which are located in many tissues and may contribute to
hyperglycemia, hyperkalemia, tachycardia and tremor.25–28
In the current study, the only statistically signiﬁcant effects
observed were on blood glucose—and these changes were
not felt to be clinically meaningful. Indacaterol demon-
strated a good overall safety proﬁle, with incidence of most
adverse events similar to, or lower than, placebo. While
all doses were well tolerated, there was an apparent
dose-relation for cough. The cough was generally rapid in
onset, mild in nature (often described as a ‘tickle in the
throat’) and short-lived (e.g. 15 s in duration). The
occurrence of cough did not persist with continued treat-
ment, and by Day 7 the incidence of cough with indacaterol
matched that of placebo.
The present study is very short and long-term studies will
be necessary to demonstrate continued safety and efﬁcacy.
Bronchodilator efﬁcacy is generally maintained over time
with long-acting b2-agonists in patients with COPD,
4,29
although diminution of bronchodilator efﬁcacy has been
described.30 Studies will also be needed to investigate the
phenomenon of cross-tolerance to the effects of rescue
bronchodilators, which is a more clinically relevant form of
tachyphylaxis.
After inhalation, indacaterol was rapidly absorbed. Serum
exposure increased in relation to dose and was subject to
slight accumulation during administration of multiple daily
doses. Administration of a 400 mg dose using the SDDPI or
MDDPI resulted in similar serum indacaterol levels, indicat-
ing that drug delivery characteristics are comparable
between the two inhalation devices. Analysis of urine
samples for indacaterol revealed that renal excretion plays
a minor role in the elimination of indacaterol.
In summary, once-daily dosing of indacaterol provided
effective 24-h bronchodilation and a fast onset of action in
subjects with COPD, with a good overall safety andtolerability proﬁle. The 400 mg dose of indacaterol, given
via either device, appeared the most effective overall in this
study, and was well tolerated. The comparison with
tiotropium suggests that the bronchodilator efﬁcacy of
indacaterol is at least as good as tiotropium. The availability
of an effective once-daily b2-agonist bronchodilator could
represent an important advance in the therapeutic arma-
mentarium used to address COPD.
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